Skip to main content
. 2016 Dec 25;8(6):9672–9685. doi: 10.18632/oncotarget.14192

Figure 4. Meta-analysis of the HR for PFS and OS for early stage ovarian cancer patients depending on LVSI status.

Figure 4

A. PFS for early stage ovarian cancer patients, fixed effects model; B. OS for early stage ovarian cancer patients, random effects model.